Psychostimulants and movement disorders

Frontiers in Neurology

Volumn 6, Issue MAR, 2015, Pages

  Asser, Andres ^a   Taba, Pille ^a  

^a UNIVERSITY OF TARTU   (Estonia)

Author keywords

[No Author keywords available]

Indexed keywords

3,4 METHYLENEDIOXYMETHAMPHETAMINE; 4' METHYLMETHCATHINONE; AMPHETAMINE; CATHINONE; COCAINE; DOPAMINE RECEPTOR; METHAMPHETAMINE; METHCATHINONE; METHYLPHENIDATE; NEUROTRANSMITTER; PSYCHOSTIMULANT AGENT;

AGITATION; ANXIETY; ARTICLE; ATTENTION DEFICIT DISORDER; BASAL GANGLION; CARDIOVASCULAR DISEASE; DEPRESSION; DISORDERS OF MITOCHONDRIAL FUNCTIONS; DOPAMINERGIC SYSTEM; DRUG ABUSE; DRUG OVERDOSE; DYSKINESIA; DYSTONIA; EUPHORIA; EXCITOTOXICITY; GABAERGIC SYSTEM; HUMAN; HYPERACTIVITY; MENTAL DISEASE; MOTOR DYSFUNCTION; NARCOLEPSY; NEUROLOGIC DISEASE; NORADRENERGIC SYSTEM; OXIDATIVE STRESS; PARKINSONISM; PATHOPHYSIOLOGY; RESTLESSNESS; SEROTONINERGIC SYSTEM; SKIN DISEASE; TREMOR;

EID: 84926433891     PISSN: None     EISSN: 16642295     Source Type: Journal    
DOI: 10.3389/fneur.2015.00075     Document Type: Article

References (159)

1. Albin RL, Young AB, Penney JB (1989). The functional anatomy of basal ganglia disorders. Trends Neurosci 12:366-75.
2. Alles GA (1933). The comparative physiological actions of the DL-bphenylisopropylamines. I. Pressor effect and toxicity. J Pharmacol Exp Ther 47, 339-354.
3. Almairac F, Herbert G, Moritz-Gasser S, Duffau H (2014). Parietal network underlying movement control: disturbances during subcortical electrostimulation. Neurosurg Rev 37(3):513-6.
4. Ares-Santos S, Granado N, Espadas I, Martinez-Murillo M, Mortalla R, (2014). Methamphetamine Causes Degeneration of Dopamine Cell Bodies and Terminals of the Nigrostriatal Pathway Evidenced by Silver Staining. Neuropsychopharmacology 39:1066-1080.
5. Attig E, Amyot R, Botez T. Cocaine induced chronic tics (1994). J Neurol Neurosurg Psychiatry 57:1143-1144.
6. Barnes NM, Sharp T (1999). A review of central 5-HT receptors and their function. Neuropharmacology 38(8):1083-1152.
7. Bartzokis G, Beckson M, Wirshing DA, Lu PH, Foster JA, Mintz J, (1999). Choreoathetoid movements in cocaine dependence. Biol Psychiatry 45: 1630-1635.
8. Bateup HS, Santini E, Shen W, Birnbaum S, Valjent E, Surmeier DJ, Fisone G, Nestler EJ, Greengard P (2010). Distinct subclasses of medium spiny neurons differentially regulate striatal motor behaviors. Proc Natl Acad Sci U S A 107(33):14845-50.
9. Bauer LO, (1996a). Psychomotor and electroencephalographic sequelae of cocaine dependence. NIDA ResMonogr 163:66- 93.
10. Bauer LO, (1996b). Resting hand tremor in abstinent cocaine-dependent, alcoholdependent, and polydrug-dependent patients. Alcohol Clin Exp Res 20: 1196-1201.
11. Bentur Y, Bloom-KrasikA, Raikhlin-Eisenkraft B (2008). Illicit cathinone (" Hagigat" ) poisoning. Clin Toxicol 46:206-210.
12. Bigsby R, LaGasse LL, Lester B, Shankaran S, Bada H, Bauer C, Liu J, (2011). Prenatal Cocaine Exposure and Motor Performance at 4 Months. Am J Occup Ther 65:e60-e68.
13. Biliński P, Kapka-Skrzypczak L, Jabłoński P (2012). Determining the scale of designer drugs (DD) abuse and risk to public health in Poland through an epidemiological study in adolescents. Ann Agric Environ Med 19:357-364.
14. Boecker H (2013). Imaging the Role of GABA in Movement Disorders. Current Neurology and Neuroscience Reports.
15. Boileau I, Rusjan P, Houle S, Wilkins D, Tong J, Selby P, Guttman M, Saint-Cyr JA, Wilson AA, Kish SJ (2008). Increased vesicular monoamine transporter binding during early abstinence in human methamphetamine users: Is VMAT2 a stable dopamine neuron biomarker? J Neurosci 28:9850-9856.
16. Bonano JS, Glennon RA, De Felice LJ, Banks ML, Negus SS (2014).Abuse-related and abuse-limiting effects of methcathinone and the synthetic "bath salts" cathinone analogs methylenedioxypyrovalerone (MDPV), methylone and mephedrone on intracranial self-stimulation in rats. Psychopharmacology 231:199-207.
17. Broadley KJ (2010).The vascular effects of trace amines and amphetamines. Pharmacol Ther 125:363-375.
18. Bruggisser M, Bodmer M and Liechti ME (2011). Severe toxicity due to injected but not oral or nasal abuse of methylphenidate tablets. Swiss Med Wkly 141:w13267.
19. BrustJC (2014). Neurologic complications of illicit drug abuse. Continuum 20:642-656.
20. Callaghan RC, Cunningham JK, Sykes J, Kish SJ (2012). Increased risk of Parkinsons disease in individuals hospitalized with conditions related to the use of methamphetamine or other amphetamine-type drugs. Drug Alcohol Depend 120:35-40.
21. Camarini R, Griffin 3rd WC, Yanke AB, Rosalina dos Santos B, Olive MF, (2008). Effects of adolescent exposure to cocaine on locomotor activity and extracel- lular dopamine and glutamate levels in nucleus accumbens of DBA/2J mice. Brain Res 1193:34-42.
22. Catalano G, Catalano MC, Rodriguez R. Dystonia associated with crack cocaine use (1997). South Med J 90:1050-1052.
23. Coppola M, Mondola R (2012).3,4-methylenedioxypyrovalerone (MDPV): chemistry pharmacology and toxicology of a new designer drug of abuse marketed online. Toxicol Lett 208:12-15.
24. Corkery J, Claridge H, Loi B, Goodair C, Chifano F (2014). Drug-related deaths in the UK: January-December 2012. Annual report 2013. International Centre for Drug Policy.
25. Cosentino C (2004). Ecstasy and acute dystonia. Mov Disord 19:1386-1387.
26. Cozzi NV, Brandt SD, Daley PF, Partilla JS, Rothman RB Tulzer A, Sitte HH, Baumann (2013). Pharmacological examination of trifluoromethyl ring-substituted methcathinone analogs. Eur J Pharmac 699:180-187.
27. De Bie RM, Gladstone RM, Strafella AP, Ko JH, Lang AE (2007). Manganese-induced Parkinsonism associated with methcathinone (Ephedrone) abuse. Arch Neurol 64: 886-889.
28. Deik A, Saunders-Pullman R, Luciano MS (2012). Substance abuse and movement disorders: complex interactions and comorbidities. Curr Drug Abuse Rev 5:243-253.
29. Den Hollander B, Rozov S, Linden AM, Uusi-Oukari M, Ojanperä I, Korpi ER (2013). Longterm cognitive and neurochemical effects of "bath salt" designer drugs methylone and mephedrone. Pharmacol Biochem Behav 103:501-509.
30. Di Matteo V, Cacchio M, Di Giulio C, Esposito E (2002). Role of serotonin 2C receptors in the control of brain dopaminergic function. Pharmacology Biochemistry and Behavior 71(4):727-34.
31. Downes MA, Whyte IM (2005). Amphetamine-induced movement disorder. Emerg Med Australas 17:277-280.
32. Dybdal-Hargreaves NF, Holder ND, Ottoson PE, Sweeney MD, Williams T (2013). Mephedrone: Public health risk, mechanisms of action, and behavioral effects. Eur J Pharmacol 714:32-40.
33. Edeleano L (1887). Über einige derivate der Phenylmethacrylsaure und der Phenylisobuttersaure. Berl Dtsch Chem Ges 20:616-622.
34. Ensing JG, (1985). Bazooka: cocaine-base and manganese carbonate. J Anal Toxicol 9:45-46.
35. Factor SA, Sanchez-Ramos JR, Wiener WJ (1988). Cocaine and Tourettes syndrome. Ann Neurol 23:423-424.
36. Fines RE, Brady WJ, DeBehnke DJ (1997). Cocaine-associated dystonic reaction. Am J EmergMed15: 513-515.
37. Fleckenstein AE, Volz TJ, Hanson GR (2009). Psychostimulant- induced alterations in vesicular monoamine transporter-2 function: neurotoxic and therapeutic implications. Neuropharmacology 56(Suppl 1):133-138.
38. Fluckiger FA, Gerock JE (1887). Contribution to the knowledge of catha leaves. Pharm J Transvaal 18:221-224.
39. Forrester MB (2012). Synthetic cathinone exposures reported to Texas poison centers. Am J Drug Alcohol Abuse 38:609-615.
40. Glasner-Edwards S, Mooney LJ, Marinelli-Casey P, Marinelli-Casey P, Hillhouse M, Ang A, Rawson R Methamphetamine Treatment Project Corporate Authors (2010). Anxiety disorders among methamphetamine dependent adults: association w i t h post-treatment functioning. Am J Addict 19:385-390.
41. Gonçalves J, Baptista S, Silva AP (2014). Psychostimulants and brain dysfunction: A review of the relevant neurotoxic effects. Neuropharmacology doi: 10.1016/j.neuropharm.2014.01.006.
42. Goodwin JS, Larson GA, Swant J, Sen N, Javitch JA, Zahniser NR, DeFelice LJ, Khoshbouei H (2009). Amphetamine and Methamphetamine Differentially Affect Dopamine Transporters in Vitro and in Vivo. Journal of Biological Chemistry 284:2978-2989.
43. Gray SD, Fatovich DM, McCoubrie DL, Daly FF (2007). Amphetamine- related presentations to an inner-city tertiary emergency department: a prospective evaluation. Med J Aust 186: 336-339.
44. Green AR, King MV, Shortall SE, Fone KC (2014). The preclinical pharmacology of mephedrone, not just MDMA by another name. Br J Pharmacol 171:2251-2268.
45. Gross NB, Duncker PC, Marshall JF, (2011). Striatal Dopamine D1 and D2 Receptors: Widespread Influences on Methamphetamine-Induced Dopamine and Serotonin Neurotoxicity. Synapse 65:1144-1155.
46. Guttmann E, Sargant W (1937). Observations on Benzedrine. Br Med J 1(3984):1013-1015.
47. Gygi MP, Gibb JW, Hanson GR (1997). Methcathinone: an initial study of its effects on monoaminergic systems. J Pharmacol Exp Ther 276:1066-1072.
48. Fleckenstein AE, Volz TJ, Riddle EL, Gibb JW, Hanson GR, (2007). New insights into the mechanism of action of amphetamines. Annu Rev Pharmacol Toxicol 47, 681-698.
49. Hagino Y, Takamatsu Y, Yamamoto H, Iwamura T, Murphy DL, Uhl GR, et al., (2011). Effects of MDMA on Extracellular Dopamine and Serotonin Levels in Mice Lacking Dopamine and/or Serotonin Transporters. Current Neuropharmacology 9:91-95.
50. Hall H, Sedvall G, Magnusson O, Kopp J, Halldin C, Farde L (1994). Distribution of D1-and D2-Dopamine Receptors, and Dopamine and Its Metabolites in the Human Brain. Neuropsychopharmacology 11(4):245-256.
51. Hall AP, Henry JA (2006). Acute toxic effects ofEcstasy (MDMA) and related compounds. overview of pathophysiology and clinical management. Br J Anaesth 96:678-685.
52. Hanlon CA, Wesley MJ, Stapleton JR, Laurienti PJ, Porrino LJ (2011). The association between frontal-striatal connectivity and sensorimotor control in cocaine users. Drug Alcohol Depend 115:240-243.
53. Hartung TK, Schofield E, Short AI, Parr MJA, Henry JA (2002). Hyponatraemic states following 3,4-methylenedioxymethamphet- amine (MDMA, ecstasy) ingestion. Q J Med 95:431-437.
54. Hay E, Shklovski V, Blaer Y, Shlakhover V, Katz A (2014).Intravenous methylphenidate: an unusual way to provoke ST-elevation myocardial infarction. Am J Emerg Med http://dx.doi.org/10.1016/j.ajem.2014.08.004.
55. Heal DJ, Smith SL, Gosden J, Nutt DJ (2013). Amphetamine, past and present - a pharmacological and clinical perspective. J Psychopharmacol 27:479-496.
56. HeinrichTW (2002). A case report of methylphenidate-induced dyskinesia. Prim Care Companion J Clin Psychiatry 4:158-159.
57. Helander A, Bäckberg M, Hulten P, Al-Saffar Y, Beck O (2014). Detection of new psychoactive substance use among emergency room patients: Results from the Swedish STRIDA project. Forensic Science International 243:23-29.
58. Hilber B, Scholze P, Dorostkar MM, Sandtner W, Holy M, Boehm S, Singer EA, Sitte HH (2005). Serotonin-transporter mediated efflux: A pharmacological analysis of amphetamines and non-amphetamines. Neuropharmacology 49(6):811-819.
59. Hildt E, Lieb K, Franke AG (2014). Life context of pharmacological academic performance enhancement among university students--a qualitative approach. BMC Med Ethics 15:23.
60. Homberg JR, De Boer SF, Raasø HS, Olivier JD, Verheul M, Ronken E, Cools AR, Ellenbroek BA, Schoffelmeer AN, Vanderschuren LJ, De Vries TJ, Cuppen E (2008). Adaptations in pre- and postsynaptic 5-HT1A receptor function and cocaine supersensitivity in serotonin transporter knockout rats. Psychopharmacology 200, 367-380.
61. Hughes JC, McCabe M, Evans RJ (1993). Intracranial haemorrhage associated with ingestion of Ecstasy. Arch Emerg Surg 10: 372-374.
62. Iversen L, White M, Treble R (2014). Designer psychostimulants: Pharmacology and differences. Neuropharmacology: In Press. DOI: 10.1016/j.neuropharm.2014.01.015
63. Kamath S, Bajaj N (2007). Crack dancing in the United Kingdom: apropos a video case presentation. Mov Disord 22:1190-1191.
64. Karch SB, Stephens BG, Ho CH (1999). Methamphetamine- related deaths in San Francisco: demographic, pathologic, and toxicologic profiles. J Forensic Sci 44: 359-368.
65. Kasick, D.P., McKnight, C.A., Klisovic, E., 2012. " Bath salts" ingestion leading to severe intoxication delirium: two cases and a brief review of the emergence of mephedrone use. Am. J. Drug Alcohol Abuse 38,176-180.
66. Kehr J, Ichinose F, Yoshitake S, Goiny M, Sievertsson T, Nyberg F, Yoshitake T (2011). Mephedrone, compared with MDMA (ecstasy) and amphetamine, rapidly increases both dopamine and 5-HT levels in nucleus accumbens of awake rats. Br J Pharmacol 164:1949-1958.
67. Kish SJ (2003). What is the evidence that Ecstasy (MDMA) can cause Parkinsons disease? Mov Disord 18:1219-1223.
68. Klein A (2014). Framing the Chew: Narratives of development, drugs and danger with regards of Khat (Catha edulis). In: Labate BC, Cavnar C (eds.), Prohibition, Religious Freedom, and Human Rights: Regulating Traditional Drug Use: 131-147.
69. Kuczenski R, Segal DS (1997). Effects of methylphenidate on extracellular dopamine, serotonin, and norepinephrine: comparison with amphetamine. J Neurochem 68:2032-2037.
70. Kuniyoshi SM, Jankovic J (2003). MDMA and parkinsonism. N Engl J Med 349:96-97.
71. Lambert BL, Bauer CR, (2012). Developmental and behavioral consequences of prenatal cocaine exposure: a review. J Perinatol 32:819-828.
72. Lane SD, Steinberg JL, Ma L, Hasan KM, Kramer LA, Zuniga EA, Narayana PA, Moeller FG, (2010). Diffusion tensor imaging and decision making in cocaine dependence. PLoS One 16;5:e11591.
73. Lim KO, Wozniak JR, Mueller BA, Franc DT, Specker SM, Rodriguez CP, Silverman AB, Rotrosen JP (2008). Brain macrostructural and microstructural abnormalities in cocaine dependence. Drug and Alcohol Dependence 92:164-172.
74. Lundh H, Tunving K (1981). An extrapyramidal choreiform syndrome caused by amphetamine addiction. J Neurol Neurosurg Psychiatry 44:728-730.
75. Malison RT, Best SE, van Dyck CH, McCance EF, Wallace EA, Laruelle M, Baldwin RM, Seibyl JP, Price LH, Kosten TR, Innis RB (1998). Elevated striatal dopamine transporters during acute cocaine abstinence as measured by [123I] beta-CIT SPECT. Am J Psychiatry 155:832-834.
76. Marsh JC, Abboudi ZH, Gibson FM, Scopes J, Daly S, O'Shaunnessy DF, Baughan AS, Gordon-Smith EC (1994). Aplastic anaemia following exposure to 3,4-methylenedioxymethamphetamine (ecstasy'). Br J Haematol 88: 281-285.
77. Marti G, Fattinger K, Zimmermann H, Exadaktylos A (2013). Orofacial dyskinesia induced by nasal Ritalin(R) (methylphenidate) sniffing: a rare case report from Switzerland. Hum Exp Toxicol 32:332-334.
78. Marusich JA, Grant KR, Blough BE, Wiley JL (2012). Effects of synthetic cathinones contained in "bath salts" on motor behavior and a functional observational battery in mice. Neurotoxicology 33:1305-1313.
79. Mash DC, Ouyang Q, Pablo J, Basile M, Izenwasser S, Lieberman A, Perrin RJ (2003). Cocaine abusers have an overexpression of a-synuclein in dopamine neurons. J Neurosci 23:2564-2571.
80. Maskell PD, De Paoli G, Seneviratne C, Pounder DJ (2011). Mephedrone (4-methylmethcathinone)-related deaths. J Anal Toxicol 35:188-191.
81. Massello W, Carpenter DA (1999). A fatality to intranasal abuse of methylphenidate (Ritalin). J Forensic Sci 44:220-221.
82. McEvoy AW, Kitchen ND, Thomas DGT (2000). Intracerebral haemorrhage and drug abuse in young adults. Br J Neurosurg 14: 449-454.
83. Mintzer S, Hickenbottom S, Gilman S (1999). Parkinsonism after taking ecstasy. N Engl J Med 340:1443.
84. Miotto K, Striebel J, Cho AK, Wang C (2013). Clinical and pharmacological aspects of bath salt use: a review of the literature and case reports. Drug Alcohol Depend 132:1-12.
85. Missale C, Nash SR, Robinson SW, Jaber M, Caron MG (1998).Dopamine receptors: from structure to function. Physiol Rev 78:189-225.
86. Morgan JC, Winter CW, Wooten GF. (2004) Amphetamine-induced chorea in attention deficit-hyperactivity disorder. Mov Disord 19: 840-842.
87. Morrow BA, Roth RH, Redmond DE, Elsworth JD (2011). Impact of methamphetamine on dopamine neurons in primates is dependent on age: implications for development Parkinsons disease. Neuroscience 189:277-285.
88. Müller CP, Carey RJ, Salloum JB, Huston JP, (2003). Serotonin1A-receptor agonism attenuates the cocaine-induced increase in serotonin levels in the hippocampus and nucleus accumbens but potentiates hyperlocomotion: an in vivo microdialysis study. Neuropharmacology 44, 592-603.
89. Nelson ME, Bryant SM, Aks SE (2014).Emerging drugs of abuse. Emerg Med Clin North Am 32:1-28.
90. Niemann A (1860). Ueber eine neue organische Base in den Cocablättern. Archiv der Pharmazie 153(2):129-155.
91. Newsome SD, Johnson E, Pardo C, McArthur JC, Nath A, (2011). Fulminant encephalopathy with basal ganglia hyperintensities in HIV-infected drug users. Neurology. 76:787-794.
92. Ohno Y, Shimizu S, Tokudome K (2013). Pathophysiological roles of serotonergic systém in regulating extrapyramidal motor functions. Biol Pharm Bull 36(9):1396-1400.
93. OSuilleabhain P, Giller C (2003). Rapidly progressive parkinsonism in a self-reported user of ecstasy and other drugs. Mov Disord 18:1378-1381.
94. Papaseit E, Farre M, Schifano F, Torrens M (2014). Emerging drugs in Europe. Curr Opin Psychiatry 27:243-250.
95. Parrott AC (2013). MDMA, serotonergic neurotoxicity, and the diverse functional deficits of recreational Ecstasy users. Neurosci Biobehav Rev 37:1466-1484.
96. Patel NB. Neurobiology of Khat (Catha edulis Forsk). In: Bentivoglio M et al. (eds.), Neglected Tropical Diseases and Conditions of the Nervous System: 307-319.
97. Pearson JM, Hargraves TL, Hair LS, Massucci CJ, Frazee CC 3rd, Garg U, Pietak BR (2012). Three fatal intoxications due to methylone. J Anal Toxicol 36:444-451.
98. Pilgrim JL, Gerostamoulos D, Drummer OH (2011). Deaths involving MDMA and the concomitant use of pharmaceutical drugs. J Anal Toxicol 35:219-226.
99. Pilgrim JL, Gerostamoulos D, Drummer OH, Bollmann M (2009). Involvement of amphetamines in sudden and unexpected death. J Forensic Sci 54:478-485.
100. Pilgrim JL, Woodford N, Drummer OH (2013). Cocaine in sudden and unexpected a review of 49 post-mortem cases. Forensic Sci Int 227:52-59.
101. Pinto JM, Babu K, Jenny C, (2013).Cocaine-induced dystonic reaction: an unlikely presentation of child neglect. Pediatr Emerg Care. 29:1006-1008.
102. Pirker S, Schwarzer C, Wieselthaler A, Sieghart W, Sperk G (2000). GABAA receptors: immunocytochemical distribution of 13 subunits in the adult rat brain. Neuroscience 101(4):815-50.
103. Priori A, Bertolasi L, Berardelli A, Manfredi M (1995). Acute dystonic reaction to ecstasy. Mov Disord 10:353.
104. Prosser JM, Nelson LS (2012). The toxicology of bath salts: a review of synthetic cathinones. J Med Toxicol 8:33-42.
105. Rasmussen N (2011). Medical science and the military: the Allies use of amphetamine during World War II. J Interdiscip Hist 42(2):205-233.
106. Regenthal R, Kruger M, Rodolf K, Trauer H, Preiss R (1999). Survival after massive ecstasy (MDMA) ingestion. Intensive Care Med 1999;25: 640-641.
107. Regunath H, Ariyamuthu VK, Dalal P, Misra M (2012). Bath salt intoxication causing acute kidney injury requiring hemodialysis. Hemodial Int 16 Suppl 1:S47-49.
108. Rhee KJ, Albertson TE, Douglas JC (1988). Choreoathetoid disorder associated with amphetamine-like drugs. Am J Emerg Med 6:131-133.
109. Ricaurte GA, Mechan AO, Yuan J, Hatzidimitriou G, Xie T, Mayne AH, McCann UD (2005). Amphetamine treatment similar to that used in the treatment of adult attention-deficit/ hyperactivity disorder damages dopaminergic nerve endings in the striatum of adult nonhuman primates. J Pharmacol Exp Ther 315:91-98.
110. Ritz MC, Cone EJ, Kuhar MJ, (1990). Cocaine inhibition of ligand binding at dopamine, norepinephrine and serotonin transporters: a structure-activity study. Life Sci 46:635-645.
111. Robottom BJ, Shulman LM, Weiner WJ (2012). Drug-Induced Movement Disorders: Emergencies and Management. Neurol Clin 30:309-320.
112. Romero MJ, Asensio S, Palau C, Sanchez A, Romero FJ, (2010). Cocaine addiction: diffusion tensor imaging study of the inferior frontal and anterior cingulate white matter. Psychiatry Res 181:57-63.
113. Rothman RB, Baumann MH (2003). Monoamine transporters and psychostimulant drugs. European Journal of Pharmacology 479:23-40.
114. Rubia K, Alegria AA, Cubillo AI, Smith AB, Brammer MJ, Radua J (2014). Effects of stimulants on brain function in attention-deficit/hyperactivity disorder: a systematic review and meta-analysis. Biol Psychiatry 76:616-628.
115. Rusyniak DE (2013). Neurologic manifestations of chronic methamphetamine abuse. Psychiatr Clin North Am 36:261-275.
116. Sadasivan S, Pond BB, Pani AK, Qu C, Jiao Y, Smeyne RJ (2012). Methylphenidate exposure induces dopamine neuron loss and activation of microglia in the basal ganglia of mice. PLoS One 7:e33693.
117. Sadeghian H (2004). Lacunar stroke associated with methylphenidate abuse. Can J Neurol Sci 31:109-111.
118. Sammler EM, Foley PL, Lauder GD, Wilson SJ, Goudzie AR, ORiordan JI (2010). A harmless high? Lancet 376:742.
119. SAMSHA (Substance Abuse and Mental Health Services Administration), Center for Behavioral Health Statistics and Quality (2014). Treatment Episode Data Set (TEDS): 2002-2012. National Admissions to Substance Abuse Treatment Services. BHSIS Series S-71, HHS Publication No. (SMA) 14-4850. Rockville, MD: Substance Abuse and Mental Health Services Administration 2014.
120. Sanotsky Y, Lesyk R, Fedoryshyn L, Komnatska I, Matviyenko Y, Fahn S (2007). Manganic encephalopathy due to "ephedrone" abuse. Mov Disord 22: 1337-1343.
121. Scharf D, (1989). Opsoclonus-myoclonus following the intranasal use of cocaine. J Neurol Neurosurg Psychiatry;52:1447-1448.
122. Schneir A, Ly BT, Casagrande K, Darracq M, Offerman SR, Thornton S, Smollin C, Vohra Rangun C, Tomaszewski C, Gerona RR (2014). Comprehensive analysis of "bath salts" purchased from California stores and the internet. Clin Toxicol 52:651-658.
123. Schifano F, Oyefeso A, Webb L, Pollard M, Corkery J, Ghodse AH (2003). Review of deaths related to taking ecstasy, England and Wales, 1997-2000. Br Med J 326: 80-81.
124. Scott JC, Woods SP, Matt GE, Meyer RA, Heaton RK, Atkinson JH, Grant I (2007). Neurocognitive effects of methamphetamine: a critical review and meta-analysis. Neuropsychol Rev 17:275-297.
125. Schouw MLJ, Gevers S, Caan MWA, Majoie cblM, Booij J, Nederveen AJ, Reneman L, (2012). Mapping serotonergic dysfunction in MDMA (ecstasy) users using pharmacological MRI. Eur Neuropsychopharmacology 22:537-545.
126. Sekine Y, Minabe Y, Ouchi Y, Takei N, Iyo M, Nakamura K, Suzuki K, Tsukada H, Okada H, Yoshikawa E, Futatsubashi M, Mori N (2003). Association of dopamine transporter loss in the orbitofrontal and dorsolateral prefrontal cortices with metham- phetaminerelated psychiatric symptoms. Am J Psychiatry 160: 1699-1701.
127. Shuen JA, Chen M, Gloss B, Calakos N (2008). Drd1a-tdTomato BAC Transgenic Mice for Simultaneous Visualization of Medium Spiny Neurons in the Direct and Indirect Pathways of the Basal Ganglia. J Neurosci 28;2681-2685
128. Shukla R, Watakabe A, Yamamori T (2014). mRNA expression profile of serotonin receptor subtypes and distribution of serotonergic terminations in marmoset brain. Front Neural Circuits 8:52
129. Simmler LD, Buser TA, Donzelli M, Schramm Y, Dieu LH, Huwyler J, Chaboz S, Hoener MC, Liechti ME (2013). Pharmacological characterization of designer cathinones in vitro. Br J Pharmacol 168:458-470.
130. Simmler LD, Rickli A, Hoener MC, Liechti ME (2014). Monoamine transporter and receptor interaction profiles of a new series of designer cathinones. Neuropharmacology 79:152-160.
131. Simonato P, Corazza O, Santonastaso P, Corkery J, Deluca P, Davey Z, Blaszko U, Schifano F (2013) Novel psychoactive substances as a novel challenge for health professionals: results from an Italian survey. Hum Psychopharmacol 28:324-331.
132. Singer LT, Moore DG, Min MO, Goodwin J, Turner JJ, Fulton S, Parrott AC (2012). Oneyear outcomes of prenatal exposure to MDMA and other recreational drugs. Pediatrics 130:407-413.
133. Sivagnanam K, Chaudari D, Lopez P, Sutherland ME, Ramu VK (2013). "Bath salts" induced severe reversible cardiomyopathy. Am J Case Rep 14:288-291.
134. Spiller HA, Hays HL, Aleguas A Jr (2013). Overdose of drugs for attention-deficit hyperactivity disorder: clinical presentation, mechanisms of toxicity, and management. CNS Drugs 27:531-543.
135. Stepens A, Groma V, Skuja S, Platkājis A, Aldiņš P, Ekšteina I, Mārtiņsone I, Bricis R, Donaghy M (2014).The outcome of the movement disorder in methcathinone abusers: clinical, MRI and manganesemia changes, and neuropathology. Eur J Neurol 21:199-205.
136. Stepens A, Stagg CJ, Platkajis A, Boudrias MH, Johansen-Berg H, Donaghy M (2010). White matter abnormalities in methcathinone abusers with an extrapyramidal syndrome. Brain 133:3676-3684.
137. Sutamtewagul G, Sood V, Nugent K (2014). Sympathomimetic syndrome, choreoathetosis, and acute kidney injury following "bath salts" injection. Clin Nephrol 81:63-66.
138. Tau GZ, Marsh R, Torres-Sanchez T, Graniello B, Hao X, Xu D, Packard MG, Duan Y, Kangarlu A, Martinez D, Peterson BS, (2014). Neural correlates of reward-based learning in persons with cocaine dependence. Neuropsychopharmacology 39:545-555.
139. Treadwell SD, Robinson TG, (2007). Cocaine use and stroke. Postgrad Med J 83:389-394.
140. Trenque T, Herlem E, Abou Taam M, Drame M (2014). Methylphenidate off-label use and safety. Springerplus Trenque T, Herlem E, Abou Taam M, Drame M (2014). Methylphenidate off-label use and safety. Springerplus 3:286.
141. UN (United Nations), General Assembly (1975). 1971 Convention on Psychotropic Substances.
142. UNODC (United Nations Office on Drugs and Crime), (2013). World Drug Report 2013. United Nations Publications.
143. Uosukainen H, Tacke U, Winstock AR (2014). Self-reported prevalence of dependence of MDMA compared to cocaine, mephedrone and ketamine among a sample of recreational poly-drug users. Int J Drug Policy pii: S0955-3959(14)00172-8.
144. Valente MJ, de Pinho PG, de Lourdes Bastos M, Carvalho F, Carvalho M, (2014). Khat and synthetic cathinones: a review. Arch Toxicol 88:15-45.
145. Varley CK, Vincent J, Varley P, Calderon R (2001). Emergence of tics in children with attention deficit hyperactivity disorder treated with stimulant medications. Compr Psychiatry 42:228-233.
146. Volkow ND, Fowler JS, Wang GJ, Hitzemann R, Logan J, Schlyer DJ, Dewey SL, Wolf AP (1993). Decreased dopamine D2 receptor availability is associated with reduced frontal metabolism in cocaine abusers. Synapse 14:169-177.
147. Vollenweider FX, Gamma A, Liechti M, Huber T (1998). Psychological and cardiovascular effects and short-term sequelae of MDMA (" ecstasy" ) in MDMA-naive healthy volunteers. Neuropsychopharmacology 19:241-251.
148. Volz TJ, Hanson GR, Fleckenstein AE, (2006). Measurement of kinetically resolved vesicular dopamine uptake and efflux using rotating disk electrode voltammetry. J. Neurosci. Methods 155:109-115.
149. Warrick, B.J., Wilson, J., Hedge, M., Freeman, S., Leonard, K., Aaron, C. (2012). Lethal serotonin syndrome after methylone and butylone ingestion. J Med Toxicol 8: 65-68.
150. Weiner WJ, Rubinstein A, Lewin B, Weiner C, Schulman LM, (2001). Cocaine-induced persistent dyskinesias. Neurology 56:964-965.
151. Wilcox JA, Wilcox AH, (2009). Movement disorders and MDMA abuse. J Psychoactive Drugs. 41:203-204.
152. Winstock A (2014). The Global Drug Survey 2014. www.globaldrugsurvey.com
153. Wood KE (2013). Exposure to Bath Salts and Synthetic Tetrahydrocannabinol from 2009 to 2012 in the United States. Journal of Pediatrics 163(1):213-216.
154. Wood DM, Davies S, Greene SL, Button J, Holt DW, Ramsey J, Dargan PI (2010). Case series of individuals with analytically confirmed acute mephedrone toxicity. Clin Toxicol 48;924-927.
155. Woods SP, Rippeth JD, Conover E, Gongvatana A, Gonzalez R, Carey CL, Cherner M, Heaton RK, Grant I; HIV Neurobehavioral Research Center Group (2005). Deficient strategic control of verbal encoding and retrieval in individuals with methamphetamine dependence. Neuropsychology 19:35-43.
156. Zawilska JB (2014). Mephedrone and other cathinones. Curr Opin Psychiatry 27:256-262.
157. Zawilska JB, Wojcieszak J (2013). Designer cathinones--an emerging class of novel recreational drugs. Forensic Sci Int 231:42-53.
158. Zhu MY, Shamburger S, Li J, Ordway GA (2000). Regulation of the human norepinephrine transporter by cocaine and amphetamine. J Pharmacol Exp Ther 295(3):951-959.
159. Young, A.C., Schwarz, E.S., Velez, L.I., Gardner, M (2013). Two cases of disseminated intravascular coagulation due to " bath salts" resulting in fatalities, with laboratory confirmation. Am J Emerg Med 31: e3-e5.